¶ Phenylpiracetam (Phenotropil)
| Type | Synthetic Nootropic (Racetam) |
| Active Isomer | (R)-Phenylpiracetam |
| Mechanism | DAT Inhibition, nAChR Modulation |
| Half-life | 3–5 hours |
| Typical Dose | 100–200 mg |
| Bioavailability | ~100% (Oral) |
| Legal Status | Rx (Russia), Unregulated (USA), Banned (WADA) |
Phenylpiracetam is a phenylated derivative of the original nootropic piracetam, developed in Russia in 1983 to enhance the physical and mental performance of cosmonauts. The addition of a phenyl group significantly increases its lipophilicity, allowing it to cross the blood-brain barrier much more efficiently than its parent compound. Unlike other racetams, phenylpiracetam exhibits potent psychostimulant effects, largely attributed to its unique ability to inhibit the dopamine transporter (DAT).
¶ At a glance
Key points
- Potent Stimulant: It is considered 20–60 times more potent than piracetam and provides immediate increases in alertness, focus, and physical stamina.
- Unique Mechanism: Unlike classical racetams, it acts as a Dopamine Transporter (DAT) inhibitor, increasing extracellular dopamine levels.
- Physical Resilience: Known for increasing tolerance to cold temperatures and physical pain, leading to its ban by the World Anti-Doping Agency (WADA).
- Rapid Tolerance: The stimulatory effects diminish quickly with daily use, making it better suited for occasional use rather than chronic supplementation.
Main Applications
- Cognitive Enhancement: Used to improve focus, memory consolidation, and mental clarity, particularly under stress.
- Physical Performance: Used by athletes (illicitly) and military personnel to sustain performance in extreme conditions.
- Neurological Recovery: Prescribed in Russia (as Phenotropil) for recovery from stroke, traumatic brain injury, and asthenia.
¶ What is Phenylpiracetam?
Phenylpiracetam (N-carbamoylmethyl-4-phenyl-2-pyrrolidone) acts as a central nervous system stimulant and nootropic. It exists as a racemic mixture of two enantiomers: (R)-phenylpiracetam and (S)-phenylpiracetam. Research indicates that the (R)-isomer is responsible for the majority of its pharmacological activity, particularly its effects on the dopamine transporter and locomotor activity[1].
¶ History and Usage
Developed at the Institute of Biomedical Problems of the Russian Academy of Sciences, it was first used to help cosmonauts cope with the prolonged stresses of space missions. It is currently sold in Russia and some Eastern European countries as a prescription drug under the brand names Phenotropil or Carphedon. It is indicated for treating cerebrovascular disorders, mood disorders (depression, apathy), and enhancing mental performance in healthy individuals[2].
¶ Mechanism of Action
Phenylpiracetam's mechanism is distinct from other members of the racetam family due to its dopaminergic activity.
¶ 1. Dopamine Transporter (DAT) Inhibition
The most defining characteristic of phenylpiracetam is its ability to bind to and inhibit the dopamine transporter (DAT). This inhibition prevents the reuptake of dopamine from the synaptic cleft, increasing extracellular dopamine levels in the striatum. The (R)-enantiomer has a significantly higher affinity for DAT (Ki ≈ 13 µM) than the (S)-enantiomer[1:1]. This mechanism underpins its psychostimulant, mood-brightening, and motivation-enhancing effects.
¶ 2. Acetylcholine and Glutamate Modulation
Like piracetam, phenylpiracetam modulates neurotransmission systems critical for memory and learning:
- nACh Receptors: It increases the density of nicotinic acetylcholine receptors (nAChRs) in the cortex and hippocampus. NMDA receptors are also upregulated, which is crucial for long-term potentiation (LTP) and memory formation[3].
- Hippocampal Proliferation: Animal studies suggest it may increase the number of NMDA receptors, potentially enhancing synaptic plasticity[4].
¶ 3. Cerebral Blood Flow and Metabolism
Phenylpiracetam improves regional blood flow in ischemic areas of the brain and stimulates cellular metabolism. It has been shown to increase glucose utilization and ATP production in neuronal cells, offering neuroprotective effects during hypoxia or ischemia[5].
¶ Benefits and Evidence
¶ Cognitive Enhancement and Stroke Recovery
Phenylpiracetam has demonstrated significant efficacy in clinical settings for neurological recovery. A large-scale study involving 400 patients with ischemic stroke found that those treated with 400 mg of phenylpiracetam daily for one year experienced significantly greater restoration of cognitive function and daily living activities compared to placebo[5:1].
In a separate study of 99 adults with encephalopathy caused by organic brain lesions, 200 mg/day of phenylpiracetam for one month led to improvements in memory, attention, and counting tasks, while also reducing anxiety and depression scores[6].
¶ Physical Performance and Cold Tolerance
One of the drug's most unique properties is its ability to increase the body's threshold for cold pain and stress. This "adaptogenic" effect makes it valuable for operations in extreme climates. Due to its potent ergogenic (performance-enhancing) effects, including increased stamina and resistance to fatigue, it is included on the WADA Prohibited List for in-competition use[7].
¶ Mood and Anxiety
Phenylpiracetam exerts anxiolytic and antidepressant effects without the sedation typical of benzodiazepines. In animal models (forced swim test), the (R)-isomer demonstrated antidepressant activity comparable to standard treatments, likely mediated by its dopaminergic action[8]. It helps counteract "asthenia" (chronic mental and physical fatigue), a primary indication for its prescription use in Russia.
¶ Evidence Summary Table
| Outcome | Effect | Consistency | Evidence Quality | Trials | Notes |
|---|---|---|---|---|---|
| Cognitive Recovery | High | Moderate | 2 RCTs | Improved function in stroke/encephalopathy patients (400mg/day)[5:2][6:1] | |
| Physical Stamina | High | Low | Animal/Obs | Banned by WADA; demonstrated in animal models[7:1][8:1] | |
| Depression/Anxiety | Moderate | Low | 1 Trial | Reduced anxiety/depression scores in encephalopathy patients[6:2] | |
| Cold Tolerance | Moderate | Low | Animal | documented in Russian prescribing info and animal data[2:1] |
¶ Dosage and Usage
¶ Standard Dosage
- Clinical Dose: 100–200 mg taken 2–3 times per day. The total daily dose typically ranges from 200 mg to 600 mg.
- Timing: Due to its stimulatory nature, it is recommended to take the last dose no later than 4:00 PM to avoid insomnia.
- Administration: It is water-soluble but highly lipophilic, so it can be taken with or without food. However, taking it with a small fat source may ensure optimal absorption.
¶ Tolerance and Cycling
Tolerance to the psychostimulant effects of phenylpiracetam develops rapidly, often within 2–3 days of consecutive use.
- Occasional Use: Best used intermittently (e.g., 1–2 times per week) for specific demanding tasks.
- Cycling: If used daily, it is often cycled (e.g., 1 week on, 2 weeks off) to maintain efficacy.
¶ Safety and Side Effects
Phenylpiracetam is generally well-tolerated when used at recommended dosages. The LD50 (lethal dose for 50% of subjects) in rodents is extremely high (800 mg/kg), indicating low toxicity[2:2].
Common Side Effects
- Insomnia: Difficulty falling asleep if taken late in the day.
- Psychomotor Agitation: Jitters, restlessness, or increased aggression in sensitive individuals.
- Headache: Common with all racetams, often attributed to acetylcholine depletion. (See "Stacks" below).
- Gastrointestinal: Nausea or stomach discomfort at high doses.
Contraindications
- Hypertension: As a stimulant, it can transiently raise blood pressure.
- Anxiety Disorders: While it has anxiolytic properties for some, its stimulatory nature can exacerbate panic or severe anxiety in others.
- Kidney/Liver Impairment: Caution is advised, as it is primarily excreted unchanged by the kidneys.
¶ Drug Interactions
- Dopaminergic Agents: Potential additive effects with other stimulants (e.g., amphetamines, methylphenidate, caffeine), increasing the risk of overstimulation and cardiovascular strain.
- Alcohol: Phenylpiracetam can reduce the sedative effects of alcohol, leading to a false sense of sobriety ("masking"), which can be dangerous.
- NMDA Antagonists: Theoretical opposition of effects, as phenylpiracetam upregulates NMDA receptors.
¶ Stacks
¶ The "Choline" Requirement
Like other racetams, phenylpiracetam increases the utilization of acetylcholine in the brain. If choline stores are depleted, this can lead to headaches and "brain fog." It is standard practice to stack phenylpiracetam with a high-quality choline source:
- Alpha-GPC: 300 mg per 100 mg of phenylpiracetam.
- CDP-Choline (Citicoline): 250 mg per 100 mg of phenylpiracetam.
¶ Pharmacokinetics
- Absorption: Rapidly and almost completely absorbed from the gastrointestinal tract (bioavailability ~100%).
- Peak Plasma Concentration: Reached within 1 hour after oral administration.
- Distribution: high lipophilicity allows it to cross the blood-brain barrier easily.
- Metabolism: It is not extensively metabolized in the body.
- Half-life: Approximately 3–5 hours in humans.
- Excretion: Approximately 40% is excreted unchanged in the urine, and 60% in bile/feces[1:2].
¶ References
Merz Pharma GmbH. (2015). Use of (R)-phenylpiracetam for the treatment of sleep disorders. European Patent EP2891491A1. https://patents.google.com/patent/EP2891491A1/en ↩︎ ↩︎ ↩︎
Malykh, A. G., & Sadaie, M. R. (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287-312. https://doi.org/10.2165/11319230-000000000-00000 ↩︎ ↩︎ ↩︎
Firstova, Y. Y., et al. (2011). The effects of scopolamine and the nootropic drug phenotropil on rat brain neurotransmitter receptors during testing of the conditioned passive avoidance task. Neurochemical Journal, 5(2), 115-125. ↩︎
Samotrueva, M. A., et al. (2011). Psychoimmunomodulatory effect of phenotropil in animals with immune stress. Bulletin of Experimental Biology and Medicine, 151(1), 51-54. https://doi.org/10.1007/s10517-011-1258-z ↩︎
Koval'chuk, V. V., et al. (2010). Efficacy of phenotropil in the rehabilitation of stroke patients. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 110(12 Pt 2), 38-40. https://pubmed.ncbi.nlm.nih.gov/21626817/ ↩︎ ↩︎ ↩︎
Savchenko, A. I., et al. (2005). The phenotropil treatment of the consequences of brain organic lesions. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 105(12), 22-26. https://pubmed.ncbi.nlm.nih.gov/16447562/ ↩︎ ↩︎ ↩︎
World Anti-Doping Agency. (2024). Prohibited List. https://www.wada-ama.org/en/prohibited-list ↩︎ ↩︎
Zvejniece, L., et al. (2011). Investigation into Stereoselective Pharmacological Activity of Phenotropil. Basic & Clinical Pharmacology & Toxicology, 109(5), 407-412. https://doi.org/10.1111/j.1742-7843.2011.00742.x ↩︎ ↩︎